|
|
|
|
|
|
Sponsored by: |
National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
Information provided by: | National Institute on Alcohol Abuse and Alcoholism (NIAAA) |
ClinicalTrials.gov Identifier: | NCT00000441 |
This project will provide relevant clinical information for primary care practitioners treating alcohol withdrawal syndrome in outpatient settings. This double-blind, placebo- controlled clinical trial will compare the effectiveness of lorazepam (Ativan) and carbamazepine (Tegretol) in alcoholics who meet the criteria for a diagnosis of uncomplicated alcohol withdrawal syndrome. Participants are randomized to five days of treatment with a 1-week posttreatment followup.
Condition | Intervention | Phase |
Alcoholism |
Drug: lorazepam (Ativan) Drug: carbamazepine (Tegretol) |
Phase IV |
MedlinePlus related topics: | Alcoholism |
Drug Information available for: | Lorazepam Carbamazepine Ethanol |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study |
Official Title: | Carbamazepine and Lorazepam in Outpatient Detoxification |
Ages Eligible for Study: | 21 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | NIAAAMAL10761 |
First Received: | November 2, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00000441 |
Health Authority: | United States: Federal Government |
|
|
|
|